| Autor: |
Landgraf R; German Diabetes Foundation, Düsseldorf, Germany., Aberle J; Division of Endocrinology and Diabetology, University Obesity Centre Hamburg, University Hospital Hamburg-Eppendorf, Germany., Birkenfeld AL; German Centre for Diabetes Research (DZD e. V.), Neuherberg, Germany., Gallwitz B; Department of Internal Medicine IV, Diabetology, Endocrinology, Nephrology, University Hospital Tübingen, Germany., Kellerer M; Department of Internal Medicine I, Marienhospital, Stuttgart, Germany., Klein HH; MVZ for Diagnostics and Therapy Bochum, Bergstraße 26, 44791 Bochum, Germany., Müller-Wieland D; Department of Internal Medicine I, Aachen University Hospital RWTH, Aachen, Germany., Nauck MA; Diabetology, Endocrinology and Metabolism Section, Department of Internal Medicine I, St. Josef Hospital, Ruhr University, Bochum, Germany., Wiesner T; MVZ Metabolic Medicine Leipzig, Leipzig, Germany., Siegel E; Department of Internal Medicine - Gastroenterology, Diabetology/Endocrinology and Nutritional Medicine, St. Josefkrankenhaus Heidelberg GmbH, Heidelberg, Germany. |
| Abstrakt: |
Competing Interests: R. Landgraf, as first author, declares the following potential conflicts of interest: Advisory boards: Lilly Deutschland, Novo Nordisk Pharma; lecture fees: Lilly Deutschland, Novo Nordisk. Other activities: Trustee of the German Diabetes Foundation, member of the steering group for the development and updating of the National Healthcare Guidelines on Diabetes.J. Aberle declares that he has received fees as a member of advisory committees and as a speaker from: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co, Merck Sharp & Dohme, Novo Nordisk, Sanofi. Institutional research funding: Boehringer Ingelheim.As co-author, B. Gallwitz declares the following potential conflicts of interest in the last 3 years: Advisory boards/consultant activities: AstraZeneca, Bayer Vital, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Novo Nordisk; lecture fees: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Novo Nordisk.Company shares: none.As co-author, M. Kellerer declares the following potential conflicts of interest: Research Support (RCT): AstraZeneca, Lilly, Novo Nordisk. Membership in advisory bodies: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novo Nordisk, Sanofi. Lecture fees: Bayer, Boehringer Ingelheim, BMS, Novartis, Merck Sharp & Dohme, Novo Nordisk.As co-author, H. H. Klein declares the following potential conflicts of interest: Advisory body: Janssen Cilag, Boehringer Ingelheim, Novartis; Lecture fee: Berlin-Chemie.As co-author, D. Müller-Wieland declares the following potential conflicts of interest: Member of the advisory board and lecture fees over the last 3 years of the following companies: Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche Diabetes Care, Sanofi.M. A. Nauck, as co-author, declares the following potential conflicts of interest: Membership of advisory committees or consultant fees: Berlin Chemie, Eli Lilly & Co., Merck Sharp & Dohme, Novo Nordisk, Regor, ShouTi (Gasherbrum); lecture fees: Berlin Chemie, Boehringer Ingelheim, Eli Lilly & Co., Medscape, Merck Sharp & Dohme, Novo Nordisk, research support: Eli Lilly & Co., Merck Sharp & Dohme, Novo Nordisk.T. Wiesner is a member of the respective advisory boards and has received lecture fees from the following companies: Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Sanofi, Berlin Chemie; Novo Nordisk. E. Siegel, as a co-author, declares that he has had no economic or personal connections with the manuscript during the last 3 years. |
